Research
Metabolic adaptation
Semaglutide represents a practice-changing therapy that addresses core pathophysiological drivers of ASCVD and HFpEF through integrated modulation of adiposity and metabolic dysfunction.
Clinicians should consider semaglutide as a key treatment option for managing ASCVD and HFpEF.
StrongSupportsmedium confidence
Semaglutide represents a practice-changing therapy that addresses core pathophysiological drivers of ASCVD and HFpEF through integrated modulation of adiposity and metabolic dysfunction.
Why this rating
Based on comprehensive review and consensus from multiple studies.
Source
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
HK Chopra et al. · Journal of the Association of Physicians of India · 2026
Meta-analysisCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →